Symbols

AXNX(Delisted)

Axonics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AXNX

Axonics, Inc.

A global medical technology company that developing novel products for bladder and bowel dysfunction

Industry

Established Date

03/02/2012

Listing Date

10/31/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

797

Fiscal Year Ends

12-31

Website

www.axonics.com

Security Type

Common stock

Office address

26 Technology Drive, Irvine, California 92618

Business

Introduction

Axonics, Inc., was incorporated in Delaware on March 2, 2012. The Company is a global medical technology company that is developing and commercializing new products for adults with bladder and bowel dysfunction, including: (i) implantable SNM systems for the treatment of urinary urgency incontinence (UUI) and urinary urgency frequency (UUF), Collectively referred to as overactive bladder (OAB), fecal incontinence (FI) and non-obstructive urinary retention (UR); (ii) urethral fillers (Bulkamin) for the treatment of stress urinary incontinence (SUI) in women.

Company Financials

EPS

AXNX has released its 2024 Q3 earnings. EPS was reported at 0, versus the expected 0.13, missing expectations. The chart below visualizes how AXNX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AXNX has released its 2024 Q3 earnings report, with revenue of 116.19M, reflecting a YoY change of 24.80%, and net profit of -21.00K, showing a YoY change of -100.53%. The Sankey diagram below clearly presents AXNX's revenue sources and cost distribution.